Video

Dr. Kahl on Remaining Challenges in Indolent Non-Hodgkin Lymphoma

Author(s):

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.

Brad S. Kahl, MD, a medical oncologist at Siteman Cancer Center and a professor of medicine in the Division of Oncology at Washington University School of Medicine in St. Louis, discusses remaining challenges in the indolent non-Hodgkin lymphoma (iNHL) treatment landscape.

Although ibrutinib (Imbruvica) and PI3K inhibitors induce a median progression-free survival of about 1 year in patients with iNHL, there is room for improved efficacy, says Kahl.

As such, future research efforts should focus on identifying additional therapies that elicit more durable responses, Kahl explains.

Notably, bispecific monoclonal antibodies that target CD3 on T cells and CD20 on B cells are currently being evaluated in iNHL. These molecules bring the T and B cells into proximity, allowing the T cells to kill the neoplastic B cells, Kahl concludes.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center